跳至主要内容
临床试验/NCT02758652
NCT02758652进行中(未招募)不适用

Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer

Tampere University Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2016年5月最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
160
试验地点
1
主要终点
miRNA expression profile as measured by miRNA array

研究概览

简要总结

Epithelial ovarian cancer is the most lethal gynecological malignancy in developed countries and the fifth most common cause of cancer-related death in women. Poor prognosis is due to challenges in early diagnosis and development of inevitable resistance to chemotherapy in majority of patients despite of good initial treatment response. The purpose of this prospective study is to analyze variation in microRNA expression in prediction of primary treatment response and the role of microRNAs in development of chemoresistance in epithelial ovarian cancer.

• Objectives: To screen microRNAs from prospectively collected plasma, urine and tumor samples from patients diagnosed with epithelial ovarian cancer. Samples are analyzed for microRNA expression and differential expression is correlated with primary treatment response, progression-free survival and overall survival.

• Methods: Plasma, urine and tumor samples are collected at primary surgery (open surgery or diagnostic laparoscopy) or interval debulking surgery, at 1st, 3rd and 6th neoadjuvant or adjuvant chemotherapy and at progression for high-throughput screening of microRNA expression by array technology.

详细描述

Inclusion criteria:

patients operated for a suspected ovarian malignancy in the Department of Obstetrics and Gynecology in Tampere University Informed consent obtained

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 18 years of age, informed consent.

排除标准

  • Informed consent not provided, age under 18 years.

结局指标

主要结局

miRNA expression profile as measured by miRNA array

时间窗: 5 years

Expression profile calculated with bioinformatical analysis

次要结局

  • Progression-free survival(5 years)
  • Over-all survival(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Annika Auranen

Chief in gynecological oncology

Tampere University Hospital

研究点 (1)

Loading locations...

相似试验

Molecular Mechanisms Leading to Chemoresistance in... | 临床试验